Dr Michel Vaillant


Dr Michel Vaillant has a background in Biology, Statistics and Epidemiology from the Universities of Montpellier and Bordeaux, France.

He has applied up-to-date statistical methods to different clinical and epidemiological studies from analysis of variance to linear mixed models or generalized mixed models in the field of neurodegenerative diseases such as Parkinson’s and Alzheimer’s.

He has developed collaborations with partners acting in Poverty Related Infectious Diseases. With a strong background in Malaria epidemiology and clinical trials, Michel has been project leader for the data management and statistics aspects of 3 large clinical trials (≈ 3400 patients) with WHO/TDR.

Michel teaches data management at the University of Metz and participates in the WHO/TDR capacity building programme, which allows African visiting scientists to be trained.

Research projects

  • MEMOLINGUA, an LIH-funded neuroimaging project with the objective to observe the functional areas of the brain that are linked to the cognitive reserve and protection against the occurrence of Cognitive Impairment. (Biostatistician) 2015-2018
  • GATIFLOXACIN: Establishment of a database for a phase 3 clinical trial of tuberculosis (gatifloxacin-containing 4-month regimen vs. standard 6-month TB regimen) in SouthAfrica, Kenya, Guinea, Senegal and Benin– 15,000 $ (validation of procedures for transfer of database) + 195,000 $, 2011-2015
  • MOXIDECTIN: Establishment of a database for a phase 3 clinical trial of onchocerciasis (moxidectin vs. standard ivermectin), Statistical Analysis and reporting in Liberia, Democratic Republic of Congo and Ghana – 128,800 $, 2012-2016
  • Project co-funded by the LIH, an anonymous donor and the National Research Fund Luxembourg (FNR) in the framework of the PROVIE program. Can non motor signs be premotor signs in Parkinson’s disease? A longitudinal multicenter case-control study. (Biostatistician) 2005-2010
  • National Research Fund Luxembourg (FNR) in the framework of the BIOSAN program. MEMOVIE, a project with the objective to examine in a prospective way, the biological factors (including genetic traits) and medical conditions associated with the occurrence and evolution of Moderate Cognitive Impairment (MCI) to Alzheimer-like Disease (AD). (Biostatistician) 2003-2012
Michel Vaillant

MS - PhD

1A-B, rue Thomas Edison
L-1445 Strassen
Tel. : +352 26 970 740

Featured Publications

Efficacy and safety of co-administered ivermectin plus albendazole for treating soil-transmitted helminths: A systematic review, meta-analysis and individual patient data analysis.

  • Competence Center for Methodology and Statistics
April 27, 2018
2018 Apr. PLoS Negl Trop Dis.12(4):e0006458.
  • Palmeirim MS
  • Hurlimann E
  • Knopp S
  • Speich B
  • Belizario V
  • Joseph SA
  • Vaillant M
  • Olliaro P
  • Keiser J.

Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.

  • Competence Center for Methodology and Statistics
April 01, 2018
2018 Apr. Lancet Infect Dis.18(4):419-430. Epub 2018 Jan 16.
  • Torrico F
  • Gascon J
  • Ortiz L
  • Alonso-Vega C
  • Pinazo M-J
  • Schijman A
  • Almeida IC
  • Alves F
  • Strub-Wourgaft N
  • Ribeiro I
  • Santina G
  • Blum B
  • Correia E
  • Garcia-Bournisen F
  • Vaillant M
  • Morales JR
  • Pinto Rocha JJ
  • Rojas Delgadillo G
  • Magne Anzoleaga HR
  • Mendoza N
  • Quechover RC
  • Caballero MYE
  • Lozano Beltran DF
  • Zalabar AM
  • Rojas Panozo L
  • Palacios Lopez A
  • Torrico Terceros D
  • Fernandez Galvez VA
  • Cardozo L
  • Cuellar G
  • Vasco Arenas RN
  • Gonzales I
  • Hoyos Delfin CF
  • Garcia L
  • Parrado R
  • de la Barra A
  • Montano N
  • Villarroel S
  • Duffy T
  • Bisio M
  • Ramirez JC
  • Duncanson F
  • Everson M
  • Daniels A
  • Asada M
  • Cox E
  • Wesche D
  • Diderichsen PM
  • Marques AF
  • Izquierdo L
  • Sender SS
  • Reverter JC
  • Morales M
  • Jimenez W.
See all publications